FDA Approves First Drug to Delay Onset of Type 1 Diabetes
FRIDAY, Nov. 18, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday approved the first drug that could delay the development of type 1 diabetes (T1D). Teplizumab (Tzield) targets the autoimmune issues that drive the disease, rather than its symptoms, making the medication a game changer. “Today’sContinue Reading